Health Condition 1: H300- Focal chorioretinal inflammation
Conditions
Interventions
Intervention1: Oral and intravitreal corticoteroids: 12 subjects randomized to Group 2 will receive standard treatment with oral corticosteroids (1 mg/kg/day) initiated at baseline and continued for a
Sponsors
PGIMER
Eligibility
Inclusion criteria
Inclusion criteria: Patients (between 19-60 years of age, either gender) with the following inclusion criteria were enrolled in the study: 1. Subjects diagnosed with active multifocal lesions of choroiditis in at least one eye involving the posterior pole. Subjects with diagnosis of either autoimmune multifocal choroiditis or TB SLC will be included in the study. 2. The disease activity confirmed on clinical examination, and imaging techniques such as optical coherence tomography, fundus autofluorescence, fluorescein angiography, and indocyanine green angiography. 3. Subjects who are treatment-naïve or those who develop active disease with
Exclusion criteria
Exclusion criteria: • Eyes in which media clarity was obscured by the presence of cataract, vitritis or any other such coexistent pathology that does not allow the acquisition of good images. • Subjects with active lesions outside the posterior pole that is no amenable to fundus imaging. • Subjects on treatment with long-term systemic immunosuppressive therapies, or those who have received intravitreal treatments in the past. In addition, subjects who have undergone pars plana vitrectomy (at any time point), cataract surgery (within the last 3 months), or glaucoma surgery (within the last 3 months) will be excluded. • Subjects who are pregnant or plan to become pregnant during the course of therapy. • Subjects with placoid choroiditis characterized by large, plaque-like lesions involving large areas of the retinochoroid. • Subjects with concomitant ocular diseases such as diabetic retinopathy, optic neuropathy, or retinal degeneration. • Patients who do not agree to come for follow-up visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean difference in the area of choriocapillaris flow deficit between the two treatment armsTimepoint: 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean difference in the best-corrected visual acuity between the two treatment armsTimepoint: 3 months;Occurrence of adverse events related to the treatment regimen in the two treatment armsTimepoint: 3 months;Time taken for the complete healing of the choroiditis lesions in the two treatment armsTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr Khushdeep Abhaypal
Post Graduate Institute of Medical Education and Research (PGIMER)
Outcome results
None listed